Denmark-based H. Lundbeck A/S has raised its financial guidance for 2022 to show projected revenue in a range of DKK 17.9 billion to DKK 18.2 billion. This compares with revenue of DKK 16.299 billion (€2.19 billion) in 2021. The upgrade follows the strong performance of its four core products, which showed double-digit increases in sales for the first nine months of the year. The products are Rexulti and Brintellix for major depressive disorder; Abilify Maintena for schizophrenia; and Vyepti, a new product for migraine prevention.
